The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).
Andres Forero-Torres
Research Funding - Seattle Genetics
Other Remuneration - Seattle Genetics
Craig Moskowitz
Consultant or Advisory Role - Seattle Genetics (U)
Research Funding - Seattle Genetics
Ranjana H. Advani
Consultant or Advisory Role - Seattle Genetics (U)
Research Funding - Seattle Genetics
Bijal D. Shah
Research Funding - Seattle Genetics
Ana Kostic
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Tina M. Albertson
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Larissa Sandalic
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Baiteng Zhao
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Michelle A. Fanale
Consultant or Advisory Role - Seattle Genetics (U)
Honoraria - Seattle Genetics
Research Funding - Seattle Genetics
Other Remuneration - Seattle Genetics